Skip to main content

Loncar Cancer Immunotherapy ETF (CNCR)

NASDAQ: CNCR · IEX Real-Time Price · USD
31.32 0.32 (1.05%)
Sep 27, 2021 4:00 PM EDT - Market closed
Expense Ratio0.79%
PE Ration/a
Shares Out1.40M
Dividend (ttm)$0.29
Dividend Yield0.93%
Ex-Dividend DateDec 30, 2020
1-Year Return
Previous Close31.00
Day's Range31.26 - 31.41
52-Week Low25.94
52-Week High35.82
Inception DateOct 13, 2015

About CNCR

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Asset ClassEquity
IssuerExchange Traded Concepts
Stock ExchangeNASDAQ
Ticker SymbolCNCR
Index TrackedLoncar Cancer Immunotherapy Index

Top 10 Holdings

42.34% of assets
Trillium Therapeutics IncTRIL.TO6.08%
Arcus BiosciencesRCUS4.86%
Instil BioTIL4.64%
ALX Oncology HoldingsALXO4.13%
Regeneron PharmaceuticalsREGN4.04%
Atara BiotherapeuticsATRA3.98%
Legend BiotechLEGN3.86%
Iovance BiotherapeuticsIOVA3.63%
Nektar TherapeuticsNKTR3.49%
View More Holdings


Ex-DividendAmountPay Date
Dec 30, 2020$0.2881193Jan 4, 2021
Dec 28, 2017$0.35019938Jan 2, 2018
Dec 29, 2015$0.10551286Jan 4, 2016
Full Dividend History


Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

1 month ago - Zacks Investment Research

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

1 month ago - GuruFocus

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

2 months ago - Kiplinger

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

4 months ago - Zacks Investment Research

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

8 months ago - Zacks Investment Research

As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally

Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...

Other symbols:IBBXBI
9 months ago - ETF Trends

Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine

Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...

Other symbols:BBHIBB
10 months ago - ETF Trends

Will Moderna Vaccine News Boost Biotech ETFs?

Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, M...

Other symbols:BBHIBB
10 months ago - ETF Trends

7 Top ETFs That Trumped Last Week's Market Rout

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

Other symbols:DWSHEPHEITB
1 year ago - Zacks Investment Research

6 Sector ETFs Surviving the Market Rout

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

1 year ago - Zacks Investment Research

5 ETFs Jump After Three-Day Rout: Will The Rally Last?

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

Other symbols:ARKQPBWPTH
1 year ago - Zacks Investment Research

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

1 year ago - Zacks Investment Research

Moderna Vaccine Optimism Could Drive Biotech ETFs

Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creatin...

Other symbols:BBHIBBXBI
1 year ago - ETF Trends

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

1 year ago - Kiplinger

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

1 year ago - InvestorPlace

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

1 year ago - Zacks Investment Research

Moderna Study Sends Biotech ETFs And Stock Futures Surging

Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...

1 year ago - ETF Trends

7 ETFs for the End of the Coronavirus

The Covid-19 pandemic dinged a slew of asset classes, but these ETFs are positioned to benefit when the virus is squashed.

1 year ago - InvestorPlace

AstraZeneca Joins Coronavirus Vaccine Race, Great For Biotech ETFs

With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.

Other symbols:AZNBBHIBBXBI
1 year ago - ETF Trends

3 ETFs For More Moderna Bets

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

Other symbols:BTECIDNA
1 year ago - Benzinga

Biotech ETFs Climbing As Moderna Builds Hope For Coronavirus Vaccine

U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...

Other symbols:IBBXBI
1 year ago - ETF Trends

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Other symbols:IBBPBEXBI
1 year ago - Zacks Investment Research

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

1 year ago - Zacks Investment Research

Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

1 year ago - Zacks Investment Research

Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

1 year ago - Zacks Investment Research